Ovid Therapeutics presents OV329 epilepsy program, targets Phase 2 data in second half of 2027
OVID•Ovid Therapeutics initiated a Phase 2 trial of OV329 in drug-resistant adult focal epilepsy, with data expected in the second half of 2027. The company also expects data from an OV329 study in the first quarter of 2027 and from OV4071 studies in the same quarter.
1. Pipeline updates
Ovid Therapeutics said its OV329 photoparoxysmal response study is underway, with data expected in the first quarter of 2027. The drug’s Phase 1 trial showed no treatment-related serious adverse events or ophthalmic changes. The company expects Phase 1 proof-of-mechanism and ketamine study data for oral KCC2 activator OV4071 in the first quarter of 2027, and plans a Phase 2 schizophrenia study of OV4071 in 2027.
